Novo Nordisk
$37.24Change from previous close: −0.41%Absolute change: −$0.16
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- $165.83B
- Enterprise value
- $180.08B
- P/E (trailing 12 months)
- 9.52
- Forward P/E
- 11.8
- Price/book
- 4.90
- Price/sales
- 3.29
- EV/EBITDA
- 6.79
- EV/revenue
- 3.58
Profitability and growth
- Gross margin
- 82.0%
- Operating margin
- 49.0%
- Net margin
- 35.3%
- ROE
- 59.8%
- ROA
- 18.7%
- ROIC
- 39.2%
Financial health
- Total cash
- $6.87B
- Total debt
- $21.41B
- Debt/equity
- 0.63
- Current ratio
- 0.87
- Quick ratio
- 0.64
- Altman Z-Score
- 4.21
- Piotroski F-Score
- 5.00
Dividends
- Annual dividend per share
- $1.28
- Dividend yield
- 3.4%
- Payout ratio
- 32.0%
- Ex-dividend date
- August 17, 2026
Analysts and estimates
- Average price target
- $45.86
- Median price target
- $44.84
- High price target
- $62.10
- Low price target
- $39.24
- Analysts with a price target
- 14
- Consensus
- Hold
- EPS estimate, current year
- $21.66
Shares and trading
- Beta
- 0.35
- Average volume
- 12.35M
- Shares outstanding
- 4.42B
- Float
- 3.17B
- Institutional ownership
- 56.3%
- Insider ownership
- 0.0%
- Short ratio (days)
- 2.51